<- Go Home
Gamida Cell Ltd.
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial. The company was incorporated in 1998 and is based in Boston, Massachusetts.
Market Cap
$2.6M
Volume
3.8M
Cash and Equivalents
$24.8M
EBITDA
-$75.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$6.5M
Profit Margin
241.92%
52 Week High
$2.51
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
-0.14
Price / Earnings
-0.04
Price / Tangible Book Value
-0.14
Enterprise Value
$55.9M
Enterprise Value / EBITDA
-0.77
Operating Income
-$78.2M
Return on Equity
363.56%
Return on Assets
-52.93
Cash and Short Term Investments
$24.8M
Debt
$78.1M
Equity
-$18.7M
Revenue
$2.7M
Unlevered FCF
-$48.5M
Sector
Biotechnology
Category
N/A